The Acinetobacter Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Acinetobacter Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acinetobacter Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued products.
GlobalData tracks 89 drugs in development for Acinetobacter Infections by 75 companies/universities/institutes. The top development phase for Acinetobacter Infections is preclinical with 48 drugs in that stage. The Acinetobacter Infections pipeline has 73 drugs in development by companies and 16 by universities/ institutes. Some of the companies in the Acinetobacter Infections pipeline products market are: Aurora Oncology, ContraFect and University of Bern.
The key targets in the Acinetobacter Infections pipeline products market include Bacterial Cell Membrane, Bacterial Cell Wall, and DNA Topoisomerase IV (EC 5.99.1.3).
The key mechanisms of action in the Acinetobacter Infections pipeline product include Bacterial Cell Membrane Disruptor with five drugs in Phase I. The Acinetobacter Infections pipeline products include six routes of administration with the top ROA being Intravenous and 15 key molecule types in the Acinetobacter Infections pipeline products market including Small Molecule, and Synthetic Peptide.
Acinetobacter Infections overview
Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, or urinary tract). Symptoms include fever and red, swollen, warm, or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene, and recent surgery or procedure.
For a complete picture of Acinetobacter Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
